Correlation Between LG Uplus and Sk Biopharmaceutica

Can any of the company-specific risk be diversified away by investing in both LG Uplus and Sk Biopharmaceutica at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining LG Uplus and Sk Biopharmaceutica into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between LG Uplus and Sk Biopharmaceuticals Co, you can compare the effects of market volatilities on LG Uplus and Sk Biopharmaceutica and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in LG Uplus with a short position of Sk Biopharmaceutica. Check out your portfolio center. Please also check ongoing floating volatility patterns of LG Uplus and Sk Biopharmaceutica.

Diversification Opportunities for LG Uplus and Sk Biopharmaceutica

-0.57

Correlation Coefficient

LG Uplus  Sk Biopharmaceutica

Excellent diversification

The 3 months correlation between 032640 and 326030 is -0.57. Overlapping area represents the amount of risk that can be diversified away by holding LG Uplus and Sk Biopharmaceuticals Co in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Sk Biopharmaceuticals and LG Uplus is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on LG Uplus are associated (or correlated) with Sk Biopharmaceutica. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Sk Biopharmaceuticals has no effect on the direction of LG Uplus i.e., LG Uplus and Sk Biopharmaceutica go up and down completely randomly.

Pair Corralation between LG Uplus and Sk Biopharmaceutica

Assuming the 90 days trading horizon LG Uplus is expected to generate 0.46 times more return on investment than Sk Biopharmaceutica. However, LG Uplus is 2.19 times less risky than Sk Biopharmaceutica. It trades about 0.12 of its potential returns per unit of risk. Sk Biopharmaceuticals Co is currently generating about -0.03 per unit of risk. If you would invest  993,000  in LG Uplus on September 22, 2024 and sell it today you would earn a total of  96,000  from holding LG Uplus or generate 9.67% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

LG Uplus  vs.  Sk Biopharmaceuticals Co

LG Uplus

Risk-Adjusted Performance

9 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in LG Uplus are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, LG Uplus may actually be approaching a critical reversion point that can send shares even higher in January 2025.

Sk Biopharmaceuticals

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Sk Biopharmaceuticals Co has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, Sk Biopharmaceutica is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.

Pair Trading with LG Uplus and Sk Biopharmaceutica

The main advantage of trading using opposite LG Uplus and Sk Biopharmaceutica positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if LG Uplus position performs unexpectedly, Sk Biopharmaceutica can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sk Biopharmaceutica will offset losses from the drop in Sk Biopharmaceutica's long position.

The idea behind LG Uplus and Sk Biopharmaceuticals Co pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.